Janux Therapeutics Inc
JANX23.739USD
+0.179+0.76%
交易中 （美东）报价延迟15分钟
1.40B总市值
亏损市盈率 TTM
关于 Janux Therapeutics Inc 公司
Janux Therapeutics, Inc. 是一家临床阶段的生物制药公司，致力于开发针对癌症的肿瘤激活免疫疗法。该公司开发了两个双特异性平台：肿瘤激活 T 细胞接合剂 (TRACTr) 和肿瘤激活免疫调节剂 (TRACIr)。TRACTr 平台生产具有肿瘤抗原结合域和 CD3 T 细胞结合域的 T 细胞接合剂 (TCE)，而 TRACIr 平台生产具有肿瘤抗原结合域和共刺激 CD28 结合域的双特异性抗体。其临床候选药物包括 JANX007 和 JANX008。JANX007 是一种前列腺特异性膜抗原 (PSMA-TRACTr)，目前正在对患有转移性去势抵抗性前列腺癌 (mCRPC) 的成年受试者进行 I 期临床试验。 JANX008 是一种表皮生长因子受体（EGFR-TRACTr），正在研究用于治疗多种实体癌，包括结直肠癌、头颈部鳞状细胞癌、非小细胞肺癌和肾细胞癌。
公司简介
公司代码JANX
公司名称Janux Therapeutics Inc
上市日期Jun 11, 2021
CEODr. David Campbell, Ph.D.
员工数量74
证券类型Ordinary Share
年结日Jun 11
公司地址10955 Vista Sorrento Parkway
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92130
电话18587514493
网址https://www.januxrx.com/
公司代码JANX
上市日期Jun 11, 2021
CEODr. David Campbell, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Independent Director
Independent Director
116.39K
+3.33%
Mr. Charles Winter
Mr. Charles Winter
Chief Technical Officer
Chief Technical Officer
74.46K
+44.70%
Ms. Janeen Doyle
Ms. Janeen Doyle
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
44.00K
--
Ms. Natasha A. Hernday
Ms. Natasha A. Hernday
Independent Director
Independent Director
3.75K
--
Dr. Ronald W. (Ron) Barrett, Ph.D.
Dr. Ronald W. (Ron) Barrett, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.75K
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
3.75K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
3.75K
--
Dr. Thomas Diraimondo, Ph.D.
Dr. Thomas Diraimondo, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Dr. David Campbell, Ph.D.
Dr. David Campbell, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Ms. Alana B. Mcnulty
Ms. Alana B. Mcnulty
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Independent Director
Independent Director
116.39K
+3.33%
Mr. Charles Winter
Mr. Charles Winter
Chief Technical Officer
Chief Technical Officer
74.46K
+44.70%
Ms. Janeen Doyle
Ms. Janeen Doyle
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
44.00K
--
Ms. Natasha A. Hernday
Ms. Natasha A. Hernday
Independent Director
Independent Director
3.75K
--
Dr. Ronald W. (Ron) Barrett, Ph.D.
Dr. Ronald W. (Ron) Barrett, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.75K
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
3.75K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月26日 周六
更新时间: 7月26日 周六
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
18.92%
Fidelity Management & Research Company LLC
14.52%
Janus Henderson Investors
7.77%
Adage Capital Management, L.P.
6.18%
Paradigm BioCapital Advisors LP
5.63%
Other
46.99%
持股股东
持股股东
占比
RA Capital Management, LP
18.92%
Fidelity Management & Research Company LLC
14.52%
Janus Henderson Investors
7.77%
Adage Capital Management, L.P.
6.18%
Paradigm BioCapital Advisors LP
5.63%
Other
46.99%
股东类型
持股股东
占比
Investment Advisor
33.46%
Hedge Fund
26.71%
Investment Advisor/Hedge Fund
24.89%
Venture Capital
21.78%
Corporation
5.07%
Private Equity
2.92%
Research Firm
2.37%
Individual Investor
1.76%
Pension Fund
0.86%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
406
71.41M
120.67%
-4.79M
2025Q1
413
73.50M
124.27%
-3.92M
2024Q4
403
71.29M
120.67%
+11.65M
2024Q3
335
56.66M
107.54%
-2.86M
2024Q2
298
57.26M
111.36%
+52.19K
2024Q1
242
56.34M
109.98%
+6.39M
2023Q4
179
48.33M
104.72%
-1.60M
2023Q3
169
48.51M
108.17%
+3.13M
2023Q2
166
43.90M
105.07%
-4.39M
2023Q1
159
44.18M
105.76%
-1.49M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
11.19M
18.92%
+3.75K
+0.03%
Jun 11, 2025
Fidelity Management & Research Company LLC
8.59M
14.52%
+28.68K
+0.33%
Mar 31, 2025
Janus Henderson Investors
4.60M
7.77%
+1.04M
+29.07%
Mar 31, 2025
Adage Capital Management, L.P.
3.65M
6.18%
+592.82K
+19.36%
Mar 31, 2025
Paradigm BioCapital Advisors LP
3.33M
5.63%
-186.08K
-5.29%
Mar 31, 2025
Bregua Corp
3.00M
5.07%
-830.27K
-21.68%
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.52M
4.25%
+116.37K
+4.85%
Mar 31, 2025
The Vanguard Group, Inc.
2.27M
3.84%
+142.33K
+6.69%
Mar 31, 2025
Cormorant Asset Management, LP
2.00M
3.38%
-100.00K
-4.76%
Mar 31, 2025
Logos Global Management LP
1.65M
2.79%
+400.00K
+32.00%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
2.63%
Tema Oncology ETF
1.73%
Virtus LifeSci Biotech Clinical Trials ETF
0.81%
SPDR S&P Biotech ETF
0.27%
Zacks Small/Mid Cap ETF
0.23%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
Invesco Nasdaq Biotechnology ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
iShares Biotechnology ETF
0.12%
T Rowe Price Small-Mid Cap ETF
0.07%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比2.63%
Tema Oncology ETF
占比1.73%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.81%
SPDR S&P Biotech ETF
占比0.27%
Zacks Small/Mid Cap ETF
占比0.23%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.16%
Invesco Nasdaq Biotechnology ETF
占比0.15%
ProShares Ultra Nasdaq Biotechnology
占比0.15%
iShares Biotechnology ETF
占比0.12%
T Rowe Price Small-Mid Cap ETF
占比0.07%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
